Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $510K (cash outflow) rose 132.9% year over year, ahead of the -7.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 109.0% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +132.9% holds above the trailing-twelve-month pace of -7.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.28M) USD
- Year-over-year change
- +39.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.28M) | +39.8% |
| FY2024 | 2024-12-31 | (2.12M) | +13.1% |
| FY2023 | 2023-12-31 | (2.44M) | -5.1% |
| FY2022 | 2022-12-31 | (2.32M) | -2.4% |
| FY2021 | 2021-12-31 | (2.27M) | — |
Capital Expenditures vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 capital expenditures of $1.57M is the 2nd largest of the 11 companies compared; the peer median is $149.1K.
- Its year-over-year change of -7.4% is the 3rd highest of 9, against a peer median of -41.3%.
- Over three fiscal years its annual growth of -18.1% compares with a peer median of -65.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.77M | -93.4% | +82.4% | 2.6% | |
| LTM Mar 2026 | $1.57M | -7.4% | -18.1% | — | |
| LTM Mar 2026 | $831K | -41.0% | -5.5% | 41.2% | |
| LTM Mar 2026 | $318.66K | -41.5% | -69.0% | 0.7% | |
| LTM Mar 2026 | $246K | -70.9% | -68.9% | 109.3% | |
| LTM Mar 2026 | $213.21K | +278.4% | -42.4% | — | |
| LTM Mar 2026 | $85K | +507.1% | -13.5% | 0.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77K | -34.2% | -78.9% | — |
| LTM Mar 2026 | $22K | -97.4% | -65.4% | 0.1% | |
| LTM Mar 2026 | $9K | — | -88.8% | 0.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding NAUT) | $149.1K | -41.3% | -65.4% | 0.7% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Depreciation & Amortization | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M |
| Change in Working Capital | (22K) | (788K) | (3.22M) | (5.46M) | (3.58M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.26M | (561K) | 393K | (578K) | (69K) |
| Other Working Capital | (1.28M) | (227K) | (3.61M) | (4.88M) | (3.52M) |
| Other Non-Cash Items | 320K | (890K) | (2.66M) | (1.96M) | (1.42M) |
| Operating Cash Flow | (39.24M) | (45.81M) | (51.71M) | (59.15M) | (50.7M) |
| Capital Expenditures | (2.27M) | (2.32M) | (2.44M) | (2.12M) | (1.28M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.8M) | (186.59M) | (112.89M) | (86.28M) | (72.49M) |
| Sales of Investments | 85.1M | 163.18M | 71.6M | 155.41M | 108.99M |
| Other Investing Activities | 0 | 0 | 0 | (760K) | 0 |
| Investing Cash Flow | (138.96M) | (25.74M) | (43.74M) | 66.25M | 35.22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (7.96M) | 562K | 368K | 1.14M | 214K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 335.41M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 327.45M | 562K | 368K | 1.14M | 214K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 149.24M | (70.98M) | (95.08M) | 8.25M | (15.26M) |
| Free Cash Flow | (41.51M) | (48.13M) | (54.15M) | (61.27M) | (51.97M) |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.